ReviewCurrent oncology reports2012
Management of hepatocellular carcinoma: beyond sorafenib.
Review in Current oncology reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Article
- Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy.World journal of gastroenterology · 2017Article
- Immunotherapeutic approaches for hepatocellular carcinoma.Oncotarget · 2017Review
- OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway.Journal of Korean medical science · 2016Article
- Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery.Scientific reports · 2016Article
- Developments in cancer vaccines for hepatocellular carcinoma.Cancer immunology, immunotherapy : CII · 2016Review
- Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection.International surgery · 2015Article
- Interventional treatment for unresectable hepatocellular carcinoma.World journal of gastroenterology · 2014Review
- Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights.World journal of gastroenterology · 2014Review
- Antiproliferative Activity of the Chinese Medicinal Compound, Delisheng, Compared With Rg3 and Gemcitabine in HepG2 Cells.Indian journal of pharmaceutical sciences · 2013Article
- Effects of hypoxia-inducible factor-1α silencing on the proliferation of CBRH-7919 hepatoma cells.World journal of gastroenterology · 2013Article
- Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma.TheScientificWorldJournal · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The positive results of sorafenib have unveiled a new direction of research in the management of hepatocellular carcinoma (HCC). Since then intensive efforts have been focused on development of novel management strategy to further improve the outcome for patients with HCC. Emerging data have suggested that tumor progression of HCC is driven by a number of deregulated signaling pathways and/or epigenetic mechanism. Thus much effort is dedicated to identification of novel agents targeting these dysregulated pathways. Combinations of targeted therapeutics and transarterial chemoembolization (TACE), or different systemic therapeutics also hold the promise to improve treatment outcome beyond sorafenib. This review aims to summarize the current status of clinical development of treatment in HCC. Perspectives on future direction of research will also be discussed.
Indexed as
Identifiers
22434314What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.